Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: A comparative study with cisplatin in rats

Archives of Toxicology

Volumn 79, Issue 8, 2005, Pages 451-460

  Uehara, Takeki ^a   Watanabe, Hiroshi ^a   Itoh, Fumio ^a   Inoue, Satoshi ^a   Koshida, Hikaru ^a   Nakamura, Masuhisa ^b   Yamate, Jyoji ^c   Maruyama, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c Osaka Prefecture University   (Japan)

Author keywords

Cisplatin; Nedaplatin; Nephrotoxicity; Papillary lesions; Rats

Indexed keywords

CISPLATIN; GAMMA GLUTAMYLTRANSFERASE; GUANOSINE TRIPHOSPHATE; HYALIN; LACTATE DEHYDROGENASE; N ACETYL BETA GLUCOSAMINIDASE; NEDAPLATIN; PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTRON MICROSCOPY; FEMALE; HYPERPLASIA; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PAPILLA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; LYSOSOME; MALE; MORPHOLOGY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; FEMALE; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TUBULES, COLLECTING; LONGEVITY; LYSOSOMES; MALE; ORGAN SIZE; ORGANOPLATINUM COMPOUNDS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 23944462200     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-005-0648-6     Document Type: Article

References (49)

1. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 31:187-192
2. Appenroth D, Braunlich H (1984) Age differences in cisplatinum nephrotoxicity. Toxicology 32:343-353
3. Appenroth D, Winnefeld K, Braunlich H (1988) Nephrotoxicity and pharmacokinetics of cisplatinum in young and adult rats. Biomed Biochim Acta 47:791-797
4. Appenroth D, Gambaryan S, Gerhardt S, Kersten L, Braunlich H (1990) Age dependent differences in the functional and morphological impairment of kidney following cisplatin administration. Exp Pathol 38:231-239
5. Bergmeyer HU, Bernt E (1974) Lactate dehydrogenase, UV-assay with pyruvate and NADH. In: Bergmeyer HU (ed) Methods of enzyme analysis, 2nd edn. Academic, New York, pp 574-579
6. Bulger RE, Dobyan DC (1984) Proliferative lesions found in rat kidneys after a single dose of cisplatin. J Natl Cancer Inst 73:1235-1242
7. Choie DD, Longnecker DS, del Campo AA (1981) Acute and chronic cisplatin nephropathy in rats. Lab Invest 44:397-402
8. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF (1982) Cis-diamminedichlorplatinum-induced acute renal failure in the rat. Kidney Int 21:54-64
9. Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 25:1-9
10. Dobyan DC (1985) Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec 212:239-245
11. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551-556
12. Dobyan DC, Hill D, Lewis T, Bulger RE (1981) Cyst formation in rat kidney induced by cis-platinum administration. Lab Invest 45:260-268
13. Flandrois C, Feldmann D, Baltassat P, Benessiano J, Berny C, Coullioud D, Coulhon-Brunet MP, Donsimoni R, Gravagna B, Berni C (1989) Evaluation of enzymuria as a tracer in nephrotoxicity: results of a multicenter study. Ann Biol Clin (Paris) 47:340-345
14. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolato-O,O) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393-396
15. Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32:685-690
16. Gomori G (1956) Histochemical methods for acid phosphatase. J Histochem Cytochem 4:453-461
17. Harauchi T, Yoshizaki T (1990) A method for determining urinary enzyme activities as nephrotoxic indicators in rats. Jpn J Pharmacol 54:205-215
18. Hofmeister R, Bhargava AS, Gunzel P (1986) Value of enzyme determinations in urine for the diagnosis of nephrotoxicity in rats. Clin Chim Acta 160:163-167
19. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19:871-877
20. Kamalakar P, Freeman AI, Higby DJ, Wallace HJ Jr, Sinks LF (1977) Clinical response and toxicity with cis-dichlorodiammineplatinum(II) in children. Cancer Treat Rep 61:835-839
21. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M (1992) Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho 19:695-701
22. Kersten L, Braunlich H, Keppler BK, Gliesing C, Wendelin M, Westphal J (1998) Comparative nephrotoxicity of some antitumour-active platinum and ruthenium complexes in rats. J Appl Toxicol 18:93-101
23. Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522-1534
24. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48:761-770
25. Litterst C, Smith JH, Smith MA, Uozumi J, Copley M (1985-1986) Sensitivity of urinary enzymes as indicators of renal toxicity of the anticancer drug cis-platin. Uremia Invest 9:111-117
26. Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100:704-713
27. Maruhn D (1976) Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta 73:453-461
28. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-244
29. Menczer J, Ben-Baruch G, Rizel S, Brenner H (1991) Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. Eur J Gynaecol Oncol 12:403-406
30. Meyer KB, Madias NE (1994) Cisplatin nephrotoxicity. Miner Electrolyte Metab 20:201-213
31. Muraoka Y, Higashiyama N, Moriyama T, Hanafusa T, Yoshizaki T, Kobayashi F (1990a) Acute toxicity study of cis-diammine(glycolato)platinum (nedaplatin), a new platinum complex, in dogs and rats. Iyakuhin Kenkyu 21:703-767
32. Muraoka Y, Itoh F, Hasegawa T, Nakano A, Hanafusa T, Yoshizaki T (1990b) One-month intravenous toxicity study of cis-diammine(glycolato)platinum (nedaplatin), a new platinum complex, in rats. Iyakuhin Kenkyu 21:803-841
33. Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA (1989) Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol 51:123-140
34. Ota K (1996) Nedaplatin. Gan To Kagaku Ryoho 23:379-387
35. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, Kimura I (1992) Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho 19:855-861
36. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST (1979) Cisplatin (cis-9-diamminedichloroplatinum II). Cancer Treat Rev 6:17-39
37. Rozencweig M, von Hoff DD, Slavik M, Muggia FM (1977) Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 86:803-812
38. Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753-758
39. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J (1986) Cisplatin nephrotoxicity. Am J Kidney Dis 8:356-367
40. Santoso JT, Lucci JA III, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13-18
41. Sharratt M, Frazer AC (1963) The sensitivity of function tests in detecting renal damage in the rat. Toxicol Appl Pharmacol 5:36-48
42. Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Fundam Appl Toxicol 10:62-72
43. Szasz G (1974) γ-Glutamyltranspeptidase. In: Bergmeyer HU (ed) Methods of enzyme analysis, 2nd edn. Academic, New York, pp 715-720
44. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Gan To Kagaku Ryoho 19:483-488
45. 195mPt]nedaplatin following intravenous administration in rats. Iyakuhin Kenkyu 26:887-895
46. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10
47. Tukey JW (1953) Some selected quick and easy methods of statistical analysis. Trans N Y Acad Sci 16:88-97
48. Ward JM, Fauvie KA (1976) The nephrotoxic effects of cis-diammine- dichloroplatinum (II) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535-547
49. Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG (1994) Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol 22:73-79